According to the Zhitong Finance App, Runmed-B (02297) announced interim results for the six months ended June 30, 2026. The group achieved revenue of 146.72 million yuan during the period, an increase of 41.01%; loss attributable to the company's shareholders was 21.989 million yuan, a year-on-year decrease of 31.65%; and a basic loss of 0.02 yuan per share.

According to the announcement, the increase in revenue was mainly due to increased sales of FlashPressure CaffR pressure sensors. Meanwhile, the Group's coronary artery amputation balloons, as a centralized procurement type, began to achieve sales revenue of about 1.39 million yuan during the reporting period. As the collection policy continues to advance and the coverage of hospitals gradually increases, the sales volume of this product is expected to increase steadily.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.